Eldred Rock Partners LLC Has $15.25 Million Stake in Thermo Fisher Scientific Inc. $TMO

Eldred Rock Partners LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,420 shares of the medical research company’s stock after purchasing an additional 1,854 shares during the period. Thermo Fisher Scientific accounts for 3.3% of Eldred Rock Partners LLC’s portfolio, making the stock its 14th largest holding. Eldred Rock Partners LLC’s holdings in Thermo Fisher Scientific were worth $15,251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the period. Darwin Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $170,000. Raymond James Financial Inc. raised its holdings in Thermo Fisher Scientific by 7.4% during the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after buying an additional 53,542 shares during the period. Finally, California State Teachers Retirement System raised its holdings in shares of Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after acquiring an additional 2,262 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 5,850 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at $8,574,720. The trade was a 28.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $574.45, for a total transaction of $2,872,250.00. Following the completion of the sale, the chief executive officer directly owned 9,608 shares in the company, valued at approximately $5,519,315.60. This represents a 34.23% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,250 shares of company stock worth $12,235,950 in the last 90 days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $593.11 on Friday. The company has a 50 day moving average of $517.63 and a 200-day moving average of $510.61. The company has a market cap of $219.30 billion, a PE ratio of 31.90, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the previous year, the firm earned $4.28 EPS. Thermo Fisher Scientific’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Piper Sandler boosted their price objective on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Barclays raised their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.